NCT05030675 2025-02-13
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
M.D. Anderson Cancer Center
Phase 1 Completed
M.D. Anderson Cancer Center
Duke University